Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 6
Semax and alcohol cravings: the evidence
No human study shows that Semax reduces alcohol cravings, and one quoted animal result cannot answer a personal safety question.
Tirzepatide and heart events: BMJ study
A 2026 BMJ cohort linked tirzepatide to fewer cardiovascular events than sitagliptin, but the result remains observational.
Tirzepatide: cardiovascular outcomes 2026
A BMJ cohort study found tirzepatide cut major cardiovascular events by 32% versus sitagliptin. Here is what the data shows.
Tirzepatide for sleep apnea
Tirzepatide reduced sleep-apnea severity in adults with obesity, but the evidence does not make it a universal substitute for CPAP.
BPC-157 and TB-500 dosing schedule
BPC-157 and TB-500 have no validated human dosing schedule. Here is what preclinical studies used, why extrapolation is unreliable, and what regulators say.
Do not pool tirzepatide vial leftovers
CDC guidance says not to pool single-dose vial leftovers. Tirzepatide presentation and dose changes should be checked with a pharmacist.
A forum peptide dose is not a minimum
No human trial has established a minimum BPC-157 or TB-500 dose for repair. The familiar forum numbers come from animal work and estimates.
Half doses do not fix peptide stacks
Using half amounts of Selank, retatrutide, or a recovery blend cannot make an unstudied peptide combination evidence based.
Peptides for injury recovery: a primer
BPC-157 and TB-500 show tissue-repair effects in animal models, but no human randomised controlled trial exists for either peptide in orthopaedic injury.
Peptides for muscle gain: a primer
Ipamorelin and CJC-1295 are the main peptides linked to muscle gain. Here is what the research shows, what it does not, and what to know before pursuing either.
Peptides for sexual function: a primer
One peptide, bremelanotide (PT-141), holds FDA approval for HSDD. Everything else is preclinical or anecdotal.
GH-axis peptides: a primer for patients
Tesamorelin, CJC-1295, and ipamorelin are the main GH-axis peptides. One has FDA approval for a specific use. The others have early-phase human data only.